Project: Cost-effective Vaccines for Female Reproductive and Infant Health
| Acronym | OptiFemVac (Reference Number: 11019) |
| Duration | 01/04/2017 - 31/03/2020 |
| Project Topic | We aim to develop vaccines targeting female reproductive and infant health, enhanced by delivery platforms designed to produce and deliver efficacious vaccines more cost effectively. The platforms allow optimal display of multiple antigens in one vaccine unit to evoke strong and long-lasting antibody and cellular responses. The main focus will be a Zika vaccine, with additional preclinical data for a combined Human Papilloma Virus (HPV) and Placental Malaria (PM) vaccine. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 6 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | ExpreS2ion Biotechnologies | Coordinator | Denmark |
| 2 | Abera | Partner | Sweden |
| 3 | University of Copenhagen | Partner | Denmark |